Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2′) enzymes

Plazomicin is currently the only next-generation aminoglycoside approved for clinical use that has the potential of evading the effects of widespread enzymatic resistance factors. However, plazomicin is still susceptible to the action of the resistance enzyme AAC(2′)-Ia from Providencia stuartii. As...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassenden, Angelia V., Dumalo, Linda, Park, Jaeok, Blanchet, Jonathan, Maiti, Krishnagopal, Arya, Dev P., Berghuis, Albert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172861/
https://www.ncbi.nlm.nih.gov/pubmed/34078922
http://dx.doi.org/10.1038/s41598-021-89446-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172861/
https://www.ncbi.nlm.nih.gov/pubmed/34078922
http://dx.doi.org/10.1038/s41598-021-89446-3

Ejemplares similares